Monday, July 4, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

Machine learning highly effective at identifying SARS-CoV-2 variants

by Medical Finance
in Coronavirus
Study: Machine learning-based approach KEVOLVE efficiently identifies SARS-CoV-2 variant-specific genomic signatures​​​​​​​. Image Credit: Metamorworks / Shutterstock
9
SHARES
103
VIEWS
Share on FacebookShare on Twitter

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causal agent of the coronavirus disease 2019 (COVID-19) pandemic, is a highly pathogenic coronavirus belonging to the betacoronavirus genus.

The genome of SARS-CoV-2 consists of a single-stranded RNA of 29,903 nucleotides. SARS-CoV-2 is associated with a very high mutation rate, and, recently, machine learning has proved to be a valuable method to identify the distinctive genomic signatures among viral sequences. This could be helpful in taxonomic and phylogenetic studies and also help in detecting emerging variants of concern. In a new study posted to the bioRxiv* preprint server, researchers studied KEVOLVE, an approach based on a genetic algorithm with a machine learning kernel, to identify several genomic signatures.

Study: Machine learning-based approach KEVOLVE efficiently identifies SARS-CoV-2 variant-specific genomic signatures​​​​​​​. Image Credit: Metamorworks / ShutterstockStudy: Machine learning-based approach KEVOLVE efficiently identifies SARS-CoV-2 variant-specific genomic signatures​​​​​​​. Image Credit: Metamorworks / Shutterstock

Machine Learning Method: KEVOLVE 

KEVOLVE includes a machine learning kernel and is based on a genetic algorithm. It identifies minimal subsets of discriminative motifs. In the context of HIV, KEVOLVE-identified motifs facilitated the construction of models that out-performed specialized HIV prediction tools, thereby demonstrating the potential of this approach. 

In the current study, researchers evaluated the KEVOLVE, whose search function was upgraded to identify smaller sets of motifs. It was important to maintain the same discriminative performance criteria. Scientists compared several reference tools to identify discriminating motifs among SARS-CoV-2 genome sequences. Four main steps were followed: (i) identification of motifs in a restricted set of nucleotide sequences, (ii) using the motifs to build prediction models and assessing them using a large set of SARS-CoV-2 sequences, (iii) analyzing the KEVOLVE-identified motifs to highlight their potential biological functions, and (iv) dedication of a specific analysis to the new Omicron variant.

SARS-CoV-2 genome organization

SARS-CoV-2 genome organization

Key Findings

In a comparative study in which scientists analyzed a large SARS-CoV-2 genome dataset, it was observed that KEVOLVE performed better in identifying variant-discriminative signatures when compared to several gold-standard reference statistical tools. 

Cluster map representing the percentage of presence of motifs identified by KEVOLVE according to the groups of variants of SARS-CoV-2.Cluster map representing the percentage of presence of motifs identified by KEVOLVE according to the groups of variants of SARS-CoV-2.

Next, the variant-discrimination motifs identified by KEVOLVE were analyzed to assess the potential functional impact of these mutations. The divergence between the genomes of SARS-CoV-2 variants was observed to be less than 1%, and the mean divergence between all the sequences was 0.29%. Omicron was observed to be the most divergent (0.44%), compared to other variants, such as Alpha, Zeta, and Iota. Overall, the variant-discriminative signatures were associated with known mutations among the different variants regarding the functional and pathological impacts based on the existing literature.

Using KEVOLVE, researchers were able to highlight three substitutions constituting unique features of Omicron: I3758V in ORF1ab (NSP6) and N679K and D796Y in ORF2. They stated that the functional implications of these mutations are unknown. Future research could investigate how these mutations could influence viral fitness and susceptibility to natural and vaccine-mediated immunity. It must be noted that the combination of N679K with H655Y and P681H could increase the cleavage of spike and, thereby, enhance fusion and viral transmission.

Nucleotide rate dissimilarity matrix and phylogenetic tree of SARS-CoV-2 variant families.

Nucleotide rate dissimilarity matrix and phylogenetic tree of SARS-CoV-2 variant families.

Implication of Results

The findings documented in the study suggest that KEVOLVE is a robust tool for the rapid and precise determination of SARS-CoV-2 variants. The genomic signatures could be used to build peptide or oligonucleotide libraries for quick pathogen detection using existing tools. Contrary to traditional methods, KEVOLVE is automatic and independent of multiple sequence alignments, a huge advantage. KEVOLVE also possesses the ability to be adapted to allow the automated analysis of previously-identified motifs, thereby increasing its efficiency even further.

Concluding Remarks

In the current study, researchers demonstrated the numerous advantages of machine learning-based tools over conventional methods to efficiently discriminate between SARS-CoV-2 variants. The new approach does not depend on multiple sequence alignment and enables users to capture mutations associated with motifs of interest. Furthermore, this detection could be done in different groups of viral pathogens.

Such methods could well be fundamental in the future to identify novel motifs pointing toward unrecognized mutations, of functional importance, in novel emerging variants. Scientists stressed that KEVOLVE could be a valuable complement to conventional genomic analyses to classify and understand viral variants.

*Important Notice

bioRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Study: Potent Neutralization of Omicron and other SARS-CoV-2 Variants of Concern by Biparatopic Human VH Domains. Image Credit: LuXiFeR Bowlo/Shutterstock

Study provides a potent biparatopic antibody against all SARS-CoV-2 variants of concern

by Medical Finance
July 4, 2022
0

In a recent study posted to the bioRxiv* preprint server, researchers demonstrated the potent neutralization of severe acute respiratory syndrome coronavirus...

Study: COVID-19-related Smell and Taste Impairment with Widespread Diffusion of SARS-CoV-2 Omicron Variant. Image Credit: Shumytskaya Olga/Shutterstock

Prevalence of chemosensory loss induced by SARS-CoV-2 Omicron variant in Italy

by Medical Finance
July 4, 2022
0

In a recent study posted to the medRxiv* preprint server, an interdisciplinary team of researchers from different countries conducted a...

Study: Fifteen Days in December: Capture and Analysis of Omicron-Related Travel Restrictions. Image Credit: Bakhtiar Zein / Shutterstock.com

Analysis of SARS-CoV-2 Omicron variant-associated travel restrictions worldwide

by Medical Finance
July 4, 2022
0

In a recent study posted to the medRxiv* preprint server, researchers evaluate the travel restrictions placed by nations worldwide following...

Study: Risk of SARS-CoV-2 reinfection 18 months after primary infection: population-level observational study. Image Credit: grebeshkovmaxim/Shutterstock

SARS-CoV-2 reinfection risk in the population of the Abruzzo Region of Italy

by Medical Finance
July 4, 2022
0

In a recent study posted to the medRxiv* preprint server, researchers evaluated the incidences of severe acute respiratory syndrome coronavirus...

Study: Covaxin (BBV152) Vaccine Neutralizes SARS-CoV-2 Delta and Omicron variants. Image Credit: Golden Shrimp / Shutterstock.com

Booster dose of Covaxin vaccine candidate neutralizes Omicron and Delta variants

by Medical Finance
July 4, 2022
0

In a recent study published on the medRxiv* preprint server, researchers evaluate the neutralization potential of sera samples from subjects...

Study: Clinical severity of Omicron sub-lineage BA.2 compared to BA.1 in South Africa. Image Credit: peterschreiber.media/Shutterstock

Severity of SARS-CoV-2 infections with Omicron BA.2 variant relative to the BA.1 variant in South Africa

by Medical Finance
July 4, 2022
0

In a recent study posted to the medRxiv* preprint server, researchers estimated the clinical severity of the severe acute respiratory syndrome...

Next Post
Study: Comparison of two T cell assays to evaluate T cell responses to SARS-CoV-2 following vaccination in naïve and convalescent healthcare workers. Image Credit: Juan Gaertner/Shutterstock

Measuring T cell responses to SARS-CoV-2 vaccination and infection in healthcare workers with two different assays

Meeting growing demand for high quality quantitative real-time PCR with Pro Universal SYBR qPCR Master Mix

Pro Universal SYBR qPCR Master Mix

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Intensive Care 620x480
    Why pregnant people were left behind while vaccines moved at ‘warp speed’ to help the masses
  • Study: Rapid characterization of a Delta-Omicron SARS-CoV-2 recombinant detected in Europe. Image Credit: Lightspring/Shutterstock
    Researchers identify novel SARS-CoV-2 Delta-Omicron recombinant strain in Europe
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply